CMC(SH:603122)2024-04-29 11:27Financial Performance - The company's operating revenue for Q1 2024 was ¥238,622,168.70, representing a decrease of 10.69% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥7,133,561.76, down 22.65% year-over-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 32.21% to ¥6,641,379.02[5]. - The company reported a net profit margin of 6.2% for Q1 2024, down from 8.5% in Q1 2023, indicating a decline in profitability[19]. - In Q1 2024, the company's net profit was CNY 7,015,684.50, a decrease of 23.0% compared to CNY 9,111,154.02 in Q1 2023[20]. - The company's operating profit decreased to CNY 10,181,445.42, down 28.3% from CNY 14,184,102.03 in Q1 2023[20]. - The company reported a total comprehensive income of CNY 6,487,291.24, down from CNY 7,207,989.32 in the same quarter last year[21]. Cash Flow and Assets - The net cash flow from operating activities was negative at -¥52,712,185.37, indicating a significant cash outflow[5]. - The net cash flow from operating activities was negative at CNY -52,712,185.37, an improvement from CNY -113,986,510.74 in Q1 2023[23]. - The company's current assets as of March 31, 2024, totaled RMB 1,270,798,589.03, an increase from RMB 1,254,796,468.80 as of December 31, 2023[15]. - Total assets at the end of the reporting period were ¥1,471,622,094.86, a slight increase of 0.70% from the end of the previous year[6]. - The company's total assets reached RMB 1,471,622,094.86 as of March 31, 2024, compared to RMB 1,461,406,215.62 at the end of 2023[17]. - Cash and cash equivalents at the end of the period were CNY 184,501,765.10, a decrease from CNY 228,813,378.42 at the end of Q1 2023[24]. Shareholder Information - Basic earnings per share remained at ¥0.02, with diluted earnings per share also at ¥0.02[6]. - The company’s basic and diluted earnings per share remained stable at CNY 0.02 for both Q1 2024 and Q1 2023[21]. - Shareholders' equity attributable to the parent company was ¥1,173,410,600.83, reflecting a 0.57% increase from the previous year[6]. Expenses and Liabilities - Total operating costs for Q1 2024 were RMB 223,741,990.22, down 9.8% from RMB 248,127,074.01 in Q1 2023[19]. - Research and development expenses increased to CNY 915,002.70, up 48.6% from CNY 616,123.18 in the previous year[20]. - Total liabilities as of March 31, 2024, were RMB 296,223,136.82, slightly up from RMB 292,494,548.82 at the end of 2023[17]. - Non-current liabilities decreased to RMB 5,659,017.44 from RMB 6,766,920.04, a reduction of 16.4%[17]. - Financial expenses showed a decrease, with interest expenses at CNY 1,130,985.73, down from CNY 1,400,022.09 in Q1 2023[20]. Revenue Decline Factors - The decline in revenue was primarily due to a decrease in customer reagent purchases and increased R&D and business expansion expenses[8].